Hong Kong, 26 Jun 2026 — Duality Biotherapeutics (DualityBio) disclosed that its Board, or delegated authority, approved the issuance of 283,500 restricted share units (RSUs) to 38 Group employees on 26 June 2026. The award, made under the company’s 2025 Share Scheme, represents 283,500 ordinary shares with no purchase price required. Based on the closing price of HK$162.80 per share on the grant date, the RSUs have an indicative market value of approximately HK$46.16 million.

The grant targets both recent hires and existing staff: • Position rewards (new joiners): 40% vests on the second anniversary of the grant date, 30% on the third, and the remaining 30% on the fourth. • Performance rewards (current employees): 40% vests after one year, followed by 30% in each of the next two years. Vesting is contingent on each recipient meeting predefined performance thresholds.

Corporate governance safeguards include automatic lapse provisions for unvested awards in events such as termination for cause, breach of transfer restrictions, or winding-up. The Board also retains discretionary clawback rights for misconduct, competitive activities, or actions detrimental to the Group’s interests.

No grantee is a director, chief executive, or substantial shareholder, and none exceeds the 1% individual limit set by Hong Kong Listing Rules; hence, shareholder approval is not required.

Following this issuance, 2.93 million ordinary shares remain available under the overall scheme mandate (initially 3.21 million shares), while the entire 0.89 million-share service-provider sublimit is still unused.